The Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie (IKP) was opened in 1973 with funding donated by Robert Bosch's eldest daughter. The institute is recognized as Germany's largest scientific research unit in the field of clinical pharmacology. In close cooperation with clinical research groups in the Robert Bosch Hospital (RBK) and external partners, the institute is dedicated to improving medical therapies. The wide variations in the effectiveness of medications in different individuals remain a major problem which approximately 75 scientists in the IKP/RBK research area are helping to solve. They also contribute to training students of medicine and life sciences at Tübingen University with more than 220 lecturing hours a year. They supervise foreign scholarship holders, guest scientists, and doctoral candidates in the fields of medicine and other science subjects.The IKP currently focuses on problems in oncology and pharmacogenetics / pharmacogenomics in the following focus areas: avoiding undesirable drug effects; inhibiting the growth of "immortal" cancer cells; the study of leukemia in children, and treatments for chronic bowel disease.
The IKP has a scientific advisory committee composed of doctors and scientists from across Germany. The committee determines the institute's research focus and is responsible for the neutral evaluation and assessment of its research projects.